GVP36 Antibody

What is GVP36 and how does it relate to the N-BAR protein family?

GVP36 is a member of the N-BAR (N-terminal Bin/Amphiphysin/Rvs) protein family in yeast. Its BAR domain shows structural similarity to those of Rvs167 and Rvs161, as determined by the Constraint-based Multiple Protein Alignment Tool and classification in the Conserved Domains Database. The N-terminal 18 residues of GVP36 form an amphipathic helix similar to those found in Rvs167 and Rvs161, confirming its classification as an N-BAR protein .

These proteins are characterized by their ability to sense and induce membrane curvature, making them crucial for various cellular processes involving membrane remodeling. The BAR domain allows these proteins to form dimers and potentially assemble into lattices on membrane surfaces.

Where is GVP36 localized in yeast cells and what is its approximate abundance?

GVP36 is a peripheral membrane protein primarily associated with the Sed5-positive early Golgi compartment in yeast cells . According to the GFP localization database, GVP36 is present at approximately 7,000 molecules per cell, making it comparable in abundance to Rvs161 .

While GVP36 can be found at endocytic sites at the plasma membrane, its presence is also significant on the endoplasmic reticulum (ER) and Golgi apparatus. Notably, up to 30% of Rvs167/GVP36 interaction events are detected at the Golgi apparatus, supporting its functional relevance at this location .

How does the mutation phenotype of GVP36 compare to other N-BAR proteins?

This phenotypic overlap yet distinct functional profile indicates that while GVP36 works cooperatively with Rvs167 in some contexts, it has evolved specialized roles, potentially related to its predominant localization at the Golgi apparatus.

What antibody-based techniques are effective for studying GVP36 interactions?

For studying GVP36 interactions, co-immunoprecipitation experiments have proven effective, particularly when coupled with epitope tagging. In published research, GFP-tagged GVP36 was successfully co-immunoprecipitated with VSV-tagged Rvs167 and Rvs161 from log-phase yeast cells . This approach revealed that both Rvs167 and Rvs161 form complexes with GVP36 in vivo, although these complexes appear to be relatively low in abundance compared to Rvs167/Rvs161 complexes.

When designing co-immunoprecipitation experiments for GVP36, researchers should consider:

• Using different epitope tags (GFP, VSV, HA, etc.) for different proteins

• Working with deletion mutant strains (e.g., rvs167Δgvp36Δ) complemented with tagged constructs

• Including appropriate controls to validate specific interactions

• Evaluating relative amounts of co-precipitated proteins to assess the abundance of different complexes

How can fluorescence-based techniques be optimized for visualizing GVP36 localization and interactions?

Bimolecular Fluorescence Complementation (BiFC) has been successfully employed to visualize GVP36 interactions with other N-BAR proteins in living cells . This technique involves fusing interacting proteins with complementary fragments of fluorescent proteins (such as Venus YFP) that reconstitute functional fluorophores when brought into proximity.

For optimal BiFC studies of GVP36:

• Fuse GVP36 and potential interaction partners with either the N-terminal (VN) or C-terminal (VC) fragments of Venus YFP at their C-termini

• Express these fusion proteins in appropriate deletion mutant backgrounds

• Cross strains expressing complementary fusion proteins to generate diploids for analysis

• Include negative controls (non-interacting proteins) and positive controls (known interacting proteins)

• Combine BiFC with mRFP markers specific for different organelles to determine the subcellular localization of interactions

• Quantify the relative frequency of interactions in different cellular compartments

The BiFC signal intensity for GVP36 interactions tends to be weaker than for other N-BAR protein combinations, suggesting technical optimization may be required .

What are the key considerations when generating antibodies against GVP36 for research applications?

When generating antibodies against GVP36 for research applications, consider:

• Epitope selection:

  • The BAR domain is highly conserved among N-BAR proteins and may lead to cross-reactivity

  • Target unique regions of GVP36 outside the BAR domain for specificity

  • Consider the N-terminal amphipathic helix (first 18 residues) as a potential specific epitope

• Expression system selection:

  • Yeast expression systems like S. cerevisiae offer advantages for studying yeast proteins

  • The AHEAD system demonstrates potential for continuous evolution of antibodies in yeast

  • Consider the yDBE (yeast Diversifying Base Editor) platform for antibody enhancement through in situ DNA diversification

• Validation strategy:

  • Confirm antibody specificity using gvp36Δ mutant strains as negative controls

  • Test for cross-reactivity with other N-BAR proteins (Rvs167, Rvs161)

  • Verify antibody performance in multiple applications (Western blotting, immunoprecipitation, immunofluorescence)

• Application-specific optimization:

  • For co-immunoprecipitation, ensure antibody binding doesn't disrupt protein-protein interactions

  • For immunofluorescence, confirm accessibility of the epitope in fixed cells

  • For flow cytometry applications, evaluate antibody performance under non-denaturing conditions

How do the interaction dynamics between GVP36 and other N-BAR proteins vary across different subcellular compartments?

The interaction dynamics between GVP36 and other N-BAR proteins show significant compartment-specific variations. BiFC experiments combined with organelle markers have revealed that:

• At the plasma membrane:

  • Rvs167/Rvs167 interactions predominate

  • Rvs167/GVP36 interactions are less frequent

  • This suggests plasma membrane N-BAR lattices may be enriched in Rvs167

• At the endoplasmic reticulum:

  • Rvs167/Rvs161 interactions predominate

  • This contrasts with the plasma membrane composition, indicating organelle-specific lattice composition

• At the Golgi apparatus:

  • Up to 30% of interaction events involve Rvs167/GVP36

  • This is notably higher than at other locations, consistent with GVP36's known association with the early Golgi compartment

These findings suggest that N-BAR proteins form lattices of variable composition in vivo, with the relative proportion of each pairing differing between organelles. This compartment-specific organization may reflect specialized functions of these protein complexes at different cellular locations.

What methodological approaches can resolve contradictions in GVP36 interaction data between in vitro and in vivo studies?

To resolve contradictions between in vitro and in vivo studies of GVP36 interactions:

• Combined analytical approach:

  • Integrate co-immunoprecipitation with BiFC visualization

  • Compare relative amounts of different protein complexes across methods

  • Use quantitative proteomics to determine stoichiometry of complexes

• Multi-condition analysis:

  • Examine interactions under different growth conditions

  • Analyze interactions at different cell cycle stages

  • Compare exponential growth phase with stationary phase

• Genetic perturbation strategies:

  • Use deletion mutants lacking specific N-BAR proteins

  • Employ domain swap experiments to identify interaction regions

  • Utilize point mutations that disrupt specific interactions (similar to P473L mutation in Rvs167)

• Structural analysis integration:

  • Combine with cryo-electron microscopy to visualize lattice organization

  • Use crosslinking mass spectrometry to map interaction interfaces

  • Apply single-molecule techniques to assess dynamics of interactions

When contradictions arise, consider that the predominantly weak interaction detected between GVP36 and other N-BAR proteins in co-immunoprecipitation experiments may reflect biological reality rather than technical limitations - GVP36 may be a minor component of N-BAR lattices in most cellular contexts except at the Golgi apparatus .

How can advanced targeting methods improve specificity when studying GVP36 in complex with other N-BAR proteins?

For improved specificity when studying GVP36 in complex with other N-BAR proteins:

• CRISPR-based approaches:

  • Employ yeast Diversifying Base Editor (yDBE) systems for targeted DNA diversification

  • Use MS2 aptamer-modified gRNA scaffolds for specific targeting

  • Consider tRNA-gRNA cassettes for multiloci targeting when studying multiple N-BAR proteins simultaneously

• Proximity labeling strategies:

  • Apply BioID or TurboID fusions to label proteins in close proximity to GVP36

  • Use APEX2 for electron microscopy-compatible proximity labeling

  • Combine with mass spectrometry for unbiased identification of interaction partners

• Single-molecule visualization techniques:

  • Implement single-molecule tracking to analyze dynamics of individual GVP36 molecules

  • Use super-resolution microscopy to resolve N-BAR lattice organization

  • Apply fluorescence correlation spectroscopy to measure interaction kinetics

• Conditional interaction systems:

  • Develop light-inducible dimerization systems for temporal control of interactions

  • Use anchor-away approaches to selectively relocalize GVP36 or its partners

  • Implement degron tags for rapid protein depletion to study interaction dependencies

These advanced targeting methods can help distinguish genuine biological interactions from experimental artifacts and provide insights into the dynamic nature of N-BAR protein complexes in living cells.

What are the optimal strain backgrounds and expression systems for studying GVP36 and its interactions?

When selecting strain backgrounds and expression systems for GVP36 research:

• Strain considerations:

  • Use deletion strains (gvp36Δ, rvs167Δ, rvs161Δ) to avoid interference from endogenous proteins

  • Consider gvp36Δrvs167Δrvs161Δ triple mutants for studying direct interactions without other N-BAR proteins

  • Evaluate strain-specific differences in membrane composition that might affect N-BAR protein behavior

• Expression level optimization:

  • For genomic integration, utilize sites known for robust transgene expression (e.g., YORWΔ22 and YPRCτ3)

  • Consider constitutive promoters like Ptdh3 for stable expression

  • Use inducible promoters (GAL) when temporal control of expression is needed

• Tagging strategy:

  • Place tags at C-terminus when studying GVP36 to avoid disrupting the N-terminal amphipathic helix

  • For N-terminal tagging, include flexible linkers to minimize functional disruption

  • Validate that tagged proteins retain wild-type localization and function

• Vector selection:

  • For stable expression, use integrative plasmids

  • For BiFC experiments, ensure compatible vector systems for crossing strains

  • Consider advanced expression systems like the tRNA-gRNA cassettes for multiloci targeting

An example approach would involve generating a gvp36Δ strain complemented with GVP36-GFP expressed from its native promoter and integrated at a neutral locus, combined with similar constructs for other N-BAR proteins using different fluorescent tags.

How can researchers address the technical challenges of detecting low-abundance GVP36 complexes?

To overcome the technical challenges associated with detecting low-abundance GVP36 complexes:

• Enhanced immunoprecipitation approaches:

  • Optimize lysis conditions to preserve membrane-associated complexes

  • Use crosslinking prior to lysis to stabilize transient interactions

  • Employ tandem affinity purification for improved purity

  • Scale up culture volumes to increase starting material

• Signal amplification methods:

  • Apply tyramide signal amplification for immunofluorescence

  • Consider proximity ligation assays for detecting protein-protein interactions

  • Use multiple epitope tags to increase detection sensitivity

• Enrichment strategies:

  • Isolate specific organelles (Golgi, ER) before analysis to concentrate relevant complexes

  • Use density gradient centrifugation to separate membrane-bound complexes

  • Apply chemical treatments that stabilize specific cellular structures

• Advanced detection technologies:

  • Implement single-molecule pull-down assays

  • Use microfluidic antibody capture devices

  • Apply quantitative mass spectrometry with isobaric labeling

The research data shows that while GVP36 forms complexes with both Rvs167 and Rvs161, these complexes appear to be of relatively low abundance in comparison to Rvs167/Rvs161 complexes . These techniques can help reveal the true biological prevalence and significance of these less abundant interactions.

What experimental controls are critical for validating GVP36 antibody specificity and interaction results?

Critical experimental controls for validating GVP36 antibody specificity and interaction results include:

• Negative controls for antibody specificity:

  • gvp36Δ mutant strains to confirm absence of signal

  • Preimmune serum controls for polyclonal antibodies

  • Isotype-matched control antibodies for monoclonal antibodies

  • Peptide competition assays to demonstrate epitope specificity

• Negative controls for interaction studies:

  • Non-interacting proteins (e.g., Bgl2 and Nic96 as used in published BiFC studies)

  • Single-tagged strains to control for non-specific signal

  • Known non-dimerizing proteins (e.g., Gyl1-Myc and Gyl1-HA that don't co-immunoprecipitate)

• Positive controls for interaction detection:

  • Known interacting proteins (e.g., Rvs167/Rvs161 for membrane-associated complexes)

  • Expression of artificial fusion proteins as technical positive controls

  • Proteins with established interaction profiles in the same subcellular compartments

• Technical validation controls:

  • Input samples to verify protein expression

  • Loading controls for normalization

  • Multiple biological and technical replicates

  • Alternative methods to confirm interactions (e.g., both co-IP and BiFC)

These controls ensure that observed signals represent genuine biological interactions rather than experimental artifacts, particularly important given the relatively weak signals observed for some GVP36 interactions.

How might emerging CRISPR-based technologies advance antibody development for studying GVP36?

Emerging CRISPR-based technologies offer promising avenues for GVP36 antibody development:

• Yeast Diversifying Base Editor (yDBE) applications:

  • The recently developed yDBE system enables targeted DNA diversification in yeast at a rate of 2.13 × 10^-4 substitutions per base over a 100 bp window

  • This approach could be used to rapidly evolve antibodies against GVP36 with improved specificity and affinity

  • yDBE has already demonstrated the ability to improve antibody affinity by over 100-fold through in situ DNA diversification coupled with yeast display

• Advanced gRNA scaffold optimization:

  • Modified gRNA scaffolds with MS2 aptamers in specific positions show enhanced activity and unique targeting profiles

  • These could be leveraged to target antibody variable regions with greater precision

  • MS2 loop placement in the first and third loops of the gRNA scaffold offers a promising starting point for optimization

• Multi-loci targeting strategies:

  • tRNA-gRNA cassettes enable efficient targeting of multiple genomic loci simultaneously

  • This could facilitate parallel optimization of heavy and light chain variable regions

  • Such approaches may yield antibodies with unprecedented specificity for distinguishing between N-BAR family members

• Integration with continuous evolution systems:

  • The AHEAD platform (a recently described in vivo continuous evolution system) demonstrates potential for isolating high-affinity nanobodies in yeast

  • Combining this approach with yDBE could create powerful workflows for GVP36-specific antibody development

  • These integrated systems could dramatically accelerate the development timeline for research antibodies

What experimental approaches can clarify the functional significance of GVP36's association with the Golgi apparatus?

To elucidate the functional significance of GVP36's association with the Golgi apparatus:

• Golgi-specific perturbation strategies:

  • Develop Golgi-specific targeting of GVP36 using organelle-specific degron systems

  • Engineer chimeric proteins that relocalize GVP36 away from the Golgi

  • Apply optogenetic tools to disrupt GVP36 Golgi localization with temporal precision

• Cargo trafficking analysis:

  • Assess trafficking of specific cargo proteins in gvp36Δ mutants

  • Develop quantitative assays for Golgi-to-plasma membrane transport

  • Analyze Golgi morphology and function under conditions that stress secretory pathways

• Interaction mapping at the Golgi:

  • Apply proximity labeling specifically at Golgi membranes

  • Identify Golgi-specific interaction partners using compartment-specific isolation

  • Compare the GVP36 interactome at the Golgi versus other locations

• Membrane dynamics analysis:

  • Measure membrane curvature at the Golgi in the presence and absence of GVP36

  • Analyze Golgi fragmentation and reassembly during cell division

  • Examine lipid composition and distribution at Golgi membranes

These approaches could help explain the observation that up to 30% of Rvs167/GVP36 interaction events occur at the Golgi apparatus , suggesting a specialized function for this N-BAR protein combination at this organelle.

How can systems biology approaches integrate diverse datasets to build comprehensive models of N-BAR protein networks?

Systems biology approaches for integrating diverse GVP36 and N-BAR protein datasets:

• Multi-omics data integration:

  • Combine proteomics, interactomics, and localisome data

  • Integrate transcriptomics data to identify co-regulated genes

  • Incorporate structural biology information on N-BAR domains and lattice formation

• Mathematical modeling approaches:

  • Develop ordinary differential equation models of N-BAR protein interactions

  • Apply agent-based modeling to simulate lattice formation on membranes

  • Use Bayesian networks to infer causal relationships between components

• Network analysis techniques:

  • Construct protein-protein interaction networks centered on N-BAR proteins

  • Identify network motifs and modules with specific functions

  • Apply graph theory to predict key nodes and edges in the network

• Comparative genomics integration:

  • Analyze evolutionary conservation of N-BAR protein interactions

  • Compare network architectures across fungal species

  • Identify conserved versus species-specific functions